

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Anthony A. Fossa

APPLICATION NO.: To be assigned

Examiner: To be assigned

FILING DATE:

Concurrently herewith

Group Art Unit: To be assigned

TITLE: COMBINATIONS OF CORTICOTROPIN

RELEASING FACTOR ANTAGONISTS AND **GROWTH HORMONE SECRETAGOGUES**

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted.

Gregory P. Raymer Attorney for Applicant(s)

Reg. No. 36,647

Pfizer Inc.

Patent Department, MS 4159

Eastern Point Road

Groton, Connecticut 06340

(860) 715-5746



INFORMATION DISCLOSURE CITATION ATTY. DOCKET NO. PC10148AGPR SERIAL NO. To be assigned (Use several sheets if necessary) **APPLICANT** Anthony A. Fossa **GROUP** FILING DATE Concurrently herewith To be assigned **U.S. PATENT DOCUMENTS** EXAMINER INITIAL FILING DATE IF APPROPRIATE DOCUMENT NUMBER NAME CLASS SUBCLASS US 6 2 08/12/86 514 Rivier et al 12 US 0 9 04/28/92 Rivier et al 530 306 US 5 3 2 1 07/21/92 Vale, Jr. et al 424 85.91 US 5 2 5 0 9 0 09/14/93 530 Kornreich et al 306 US 5 6 4 8 7 4 11/07/95 Courtemanche et al 514 342 US 5 9 3 0 0 6 02/20/96 de Miranda et al 530 306 Kornreich et al US 5 5 0 5 8 04/23/96 530 306 US 5 6 5 4 4 0 7 07/01/97 Yuan et al 544 280 US 5 6 6 9 3 2 2 09/02/97 Rivier 530 306 US 5 6 6 8 4 09/16/97 1 5 **Bright** 514 307 US 7 5 0 5 6 4 6 01/06/98 Bright et al 546 144 US 5 7 2 3 0 01/27/98 3 Faraci et al 407 514 US 7 5 2 6 0 8 04/03/98 Yuan 544 283 US 5 0 6 3 2 4 5 11/05/91 Abreu et al 514 404 US 5 2 0 6 2 3 5 04/27/93 Fisher et al 514 213 US 8 1 02/01/94 Bochis et al 514 183 US 5 4 9 2 9 02/20/96 Morriello et al 1 6 514 318 **FOREIGN PATENT DOCUMENTS** DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO wo 9 5 3 3 7 5 0 14.12.95 International C07D 487/04 WO 9 6 5 3 5 3 21.12.95 International C07D 471/04 WO 9 1 3 6 6 1 23.06.94 International C07D 401/06 WO 9 3 6 1 23.06.94 International C07D 231/44 wo 9 4 1 3 6 4 3 23.06.94 International C07D 231/44 wo 9 1 3 6 7 6 23.06.94 International **C07D** 487/04

À	
1	

INFORMATION DISCLOSURE CITATION ATTY, DOCKET NO. PC10148AGPR SERIAL NO. To be assigned															
INFORI	MATI	ION DIS	CLOS	URE CIT	ATION		TY. DOC	To be assigned							
(Use several sheets if necessary)							PLICAN	Γ Ant	hony A. F	T					
							ING DAT	ΓΕ Cond	currently h	nerewith	GROUP	To be	To be assigned		
	wo	9	4	1	3	6_	6 7 7 23.06.94 Internation		Internation	al C07D	487/04				
	wo	9	5	3	3	7	2	7	14.12.95	Internation	al C07D	231/12			
	wo	9	88	0	5	6	6	1	12.02.98	Internation	al C07D	471/04			
	wo	9	8	0	8	8	4	7_	05.03.98	Internation	al C07D	487/04			
	wo	9	8	0	8	8	4	6	05.03.98	Internation	al C07D	471/04			
	EP	7	7	8	2	7	7		11.06.97	Europe	C07D	487/04			
	EΡ	7	7	3	0	2	3		14.05.97	Europe	A61K	31/435			
*	EP	5	7	6	3	5	0		29.10.97	Europe	C07D	277/42			
*	EP	6	5	9	7	4	7		01.04.98	Europe	C07D	277/42			
	EP	8	1	2	8	3	1		17.12.97	Europe	C07D	235/08			
	wo	9	5	1	0	5	0	6	20.04.95	Europe	C07D	239/42			
	wo	9	6	3	5	6	8	9	14.11.96	Europe	C07D	471/04			
	wo	9	6	3	5	6	8	9	12.12.96	Internation	al C07D	285/08			
	wo	9	6	3	9	4	0	0	09.01.97	Internation	al C07D	277/42			
	wo	9	7	0	0	8	6	8	09.01.97	Internation	al C07D	277/42			
	wo	9	7	11	4	6	8	4	24.04.97	Internation	al C07D	239/42			
	wo	9	7	2	9	1	0	9	14.08.97	Internation	al C07D	487/04			
	wo	9	7	2	9	1	1	0	14.08.97	Internation	al C07D	495/04			
	wo	9	7	3	5	5	3	9	02.10.97	Internation	al A61K				
	wo	9	7	3	5	5	8	0	02.10.97	Internation	al A61K	31/505			
	wo	9	7	3	5	8	4	6	02.10.97	Internation	al C07D	249/00			
	wo	9	7	4	4	0	3	8	27.11.97	Internation	al A61K	31/495			
	wo	9	7	4	5	4	2	1	04.12.97	Internation	al C07D	311/56			
	wo	9	8	0	3	5	1.	0	29.01.98	Internation	al C07D	487/04			
	wo	9	8	0	8	8	2	1	05.03.98	Internation	al C07D	239/00			
	wo	9	8	1	1	0	7	5	19.03.98	Internationa	al C07D	241/20			
	wo	9	8	11	5	5	4	3	16.04.98	Internation	al C07D	277/42			

INFORMATION DISCLOSURE CITATION							TY. DOC	KET NO	D. PC1014	SERIAL NO. To be assigned			
(Use several sheets if necessary)							PLICAN						
				т	 	FIL	ING DAT	TE Con	currently h	GROUP To be assigned			
	wo	9	8	2	1	2	0_	0	22.05.98	Internation	International C07D		
	wo	9	8	2	7	0	6	6	25.06.98	Internation	al C07D	237/34	
*	wo	9	8	2	9	3	9	7	09.07.98	Japan	Japan C07D		
	wo	9	8	2	9	4	1	3	09.07.98	Internation	International C07D		
*	wo	9	8	4	2	6	9	9	01.10.98	Japan	C07D	401/04	
	wo	9	8	3	5	9	6	7	20.08.98	Internation	al C07D	487/00	
	wo	9	8	4	2	7	0	6	01.10.98	Internation	al C07D	471/04	
	wo	9	8	4	5	2	9	5	15.10.98	Internation	al C07D	471/04	
	wo	9	8	4	7	8	7	4	29.10.98	Internation	al C07D	215/42	
	wo	9	8	4	7	9	0	3	29.10.98	Internation	al C07D	495/04	
	wo	9	8	5	1	3	1	2	19/11/98	Internationa	al A61K	31/54	
	wo	9	9	0	1	4	5	4	14.01.99	Internationa	International C07D		
	wo	9	9	0	1	4	3	9	14.01.99	Internationa	al C07D	239/42	
	wo.	9	9	1	0	3	5	0 -	04.03.99	Internationa	al C07D	487/04	
	wo	9	9	1	2	9	0	8	18.03.99	Internationa	al C07D	215/42	
*	wo	9	9	0	o	3	7	3	07.01.99	Japan	C07D	235/08	
	wo	9	9	3	8	8	6	8	05.08.99	Internationa	al C07D	487/04	
	wo	9	9	5	1	5	9	7	14.10.99	Internationa	al C07D	471/04	
	wo	9	9	5	1	5	9	9	14.10.99	Internationa	al C07D	471/04	
	wo	9	9	4	0	0	8	9	12.08.99	Internationa	al C07D	417/12	
	wo	9	9	5	1	5	9	88	14.10.99	Internationa	al C07D	471/04	
	wo	9	9	5	1	6	0	0	14.10.99	Internationa	al C07D	471/04	
	wo	9	7	2	4	3	6	9	10.07.97	Internationa	al C07K	5/06	
	wo	9	8	5	8	9	4	7	30.12.98	Internationa	al C07K	5/023	
	wo	9	7	4	1	8	7	9	13.11.97	Internationa	al A61K	38/00	
	wo	9	8	5	8	9	5	0	30.12.98	Internationa	al C07K	5/08	



INF	INFORMATION DISCLOSURE CITATION				АТ	TY. DOC	KET NC). PC101	SERIAL NO. To be assigned								
	(Use several sheets if necessary)					API	PLICAN	Γ Ant									
								ING DA	ΓΕ Cond	urrently I	GROUP To be			assiç	gned		
											<u> </u>		i i				
	_						 -		<u> </u>		<u> </u>		<u> </u>		 	<u> </u>	
				0711	FD D00		TO (1	 		 	D		<u> </u>		<u> </u>		
<u> </u>	T	Т	T -	ОТН	ER DOC	UMEN	15 (Inc	iuaing A	utnor, 11	tie, Date,	Pertinent Pa	iges, i	Etc.)				
			T. E. 0	Christos,	et al., Exp	. Opin. Th	er. Pate	nts (1998)	8(2):143-	152, "Cortic	otrophin-releasi	ng fact	or receptor a	antagonists	s"		
		^	P. Bla	ck, Scien	ntific Ameri	can: "Scie	ence & N	Medicine,"	1995, 2:16	-25, "							
								ceutical Design, 1995, 1:305-316, "Corticotropin-Releasing Factor Receptors: Inhibitors, n, and Their Role in Central Nervous System Function".									
		<u> </u>			et al., Tre		armacol	ogical Scie	ences, Apr	il 1996, pag	ges 166-172, "Co	orticotro	ophin-releas	ing recept	ors: fro	m	
			M. J. 0	Owens et	al., 1991,	Pharm, F	Rev., 43:4	425-473, "	Physiology	and Pharn	nacology of Cor	ticotrop	in-releasing	Factor".			
	ļ													<u> </u>	_	<u> </u>	
		*	Will ha	ave transl	lated and s	end whe	n availat	ole.			<u> </u>			<u>م</u> و			
		^	Will se	end when	available.									2,5		3	
				,										40		7	
	<u> </u>		1										<u>-</u>	T V			
-	<u> </u>								<u> </u>								
	<u> </u>				·												
																•	
														············			
	l		<u> </u>														
	ļ		<u> </u>														
			<u> </u>							-							
																	
EXAMI	NER								DATE CO	ONSIDERE	D						
EXAMINE next com	:R: Initi nunicat	al if refe ion to ap	rence consoplicant.	sidered, whe	ther or not cit	ation is in co	nformance	with MPEP 60	9; Draw line t	hrough citation	if not in conformance	and not	considered. Incl	ude copy of th	is form w	ith	

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE